Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

How to buy Antares Pharma stock | 3.28

Own Antares Pharma stock in just a few minutes.

Posted

Fact checked

Antares Pharma, Inc is a medical instruments & supplies business based in the US. Antares Pharma shares (ATRS) are listed on the NASDAQ and all prices are listed in US Dollars. Antares Pharma employs 178 staff and has a trailing 12-month revenue of around USD$137.6 million.

How to buy shares in Antares Pharma

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Antares Pharma. Find the stock by name or ticker symbol: ATRS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Antares Pharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$3.28, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Antares Pharma, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Antares Pharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Antares Pharma's share price?

Since the stock market crash in March caused by coronavirus, Antares Pharma's share price has had significant negative movement.

Its last market close was USD$3.28, which is 7.08% down on its pre-crash value of USD$3.53 and 105.00% up on the lowest point reached during the March crash when the shares fell as low as USD$1.6.

If you had bought USD$1,000 worth of Antares Pharma shares at the start of February 2020, those shares would have been worth USD$516.57 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$906.07.

Antares Pharma share price

Use our graph to track the performance of ATRS stocks over time.

Antares Pharma shares at a glance

Information last updated 2020-10-20.
Latest market closeUSD$3.28
52-week rangeUSD$1.6 - USD$5.13
50-day moving average USD$2.8979
200-day moving average USD$2.8185
Wall St. target priceUSD$6.25
PE ratio 84.8176
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.034

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks
N/A
0%
A free way to invest in stocks, ETFs and crypto.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Tastyworks
$0
Stocks, Options, ETFs, Futures
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Antares Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Antares Pharma price performance over time

Historical closes compared with the close of $3.28 from 2020-10-19

1 week (2020-10-14) -2.09%
1 month (2020-09-21) 17.99%
3 months (2020-07-21) 14.29%
6 months (2020-04-21) 24.71%
1 year (2019-10-21) -5.20%
2 years (2018-10-19) -1.80%
3 years (2017-10-20) 50.46%
5 years (2015-10-21) 146.62%

Is Antares Pharma under- or over-valued?

Valuing Antares Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Antares Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Antares Pharma's P/E ratio

Antares Pharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 85x. In other words, Antares Pharma shares trade at around 85x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Antares Pharma's EBITDA

Antares Pharma's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$11.6 million.

The EBITDA is a measure of a Antares Pharma's overall financial performance and is widely used to measure a its profitability.

Antares Pharma financials

Revenue TTM USD$137.6 million
Operating margin TTM 6.71%
Gross profit TTM USD$73.4 million
Return on assets TTM 4.57%
Return on equity TTM 11.24%
Profit margin 4.04%
Book value $0.345
Market capitalisation USD$544.8 million

TTM: trailing 12 months

Shorting Antares Pharma shares

There are currently 4.2 million Antares Pharma shares held short by investors – that's known as Antares Pharma's "short interest". This figure is 13.3% down from 4.8 million last month.

There are a few different ways that this level of interest in shorting Antares Pharma shares can be evaluated.

Antares Pharma's "short interest ratio" (SIR)

Antares Pharma's "short interest ratio" (SIR) is the quantity of Antares Pharma shares currently shorted divided by the average quantity of Antares Pharma shares traded daily (recently around 826686.33663366). Antares Pharma's SIR currently stands at 5.05. In other words for every 100,000 Antares Pharma shares traded daily on the market, roughly 5050 shares are currently held short.

However Antares Pharma's short interest can also be evaluated against the total number of Antares Pharma shares, or, against the total number of tradable Antares Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Antares Pharma's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Antares Pharma shares in existence, roughly 30 shares are currently held short) or 0.0256% of the tradable shares (for every 100,000 tradable Antares Pharma shares, roughly 26 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Antares Pharma.

Find out more about how you can short Antares Pharma stock.

Antares Pharma share dividends

We're not expecting Antares Pharma to pay a dividend over the next 12 months.

Have Antares Pharma's shares ever split?

Antares Pharma's shares were split on a 1:5 basis on 29 January 1999. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Antares Pharma shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Antares Pharma shares which in turn could have impacted Antares Pharma's share price.

Antares Pharma share price volatility

Over the last 12 months, Antares Pharma's shares have ranged in value from as little as $1.6 up to $5.13. A popular way to gauge a stock's volatility is its "beta".

ATRS.US volatility(beta: 1.23)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Antares Pharma's is 1.2306. This would suggest that Antares Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Antares Pharma overview

Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., Idorsia Pharmaceuticals Ltd, and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.

Frequently asked questions

More guides on finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site